Risks

Working-capital intensity remains elevated, with a 401-day cash conversion cycle versus leaner peers, which can constrain cash generation and funding flexibility.

Receivables collection is slow at 211 days outstanding, increasing exposure to reimbursement timing and counterparty delays relative to faster-turning healthcare peers.

Inventory days of 236 suggest capital is tied up longer than in more efficient device distributors, which can pressure liquidity if demand softens or mix shifts.

Net debt to EBITDA of 1.4x is manageable but still leaves BGMS more exposed than net-cash peers if margins weaken or growth capital needs rise.

Interest coverage is not meaningful in the provided data, so peers with clearer earnings coverage may be better positioned if rates stay elevated or refinancing tightens.

Opportunities

A current ratio of 8.6x and quick ratio of 7.2x indicate unusually strong short-term liquidity versus peers, supporting growth execution and supplier confidence.

Moderate leverage at 1.4x net debt to EBITDA gives BGMS more balance-sheet capacity than highly levered peers to absorb working-capital swings and fund expansion.

The long cash cycle can also reflect scale in reimbursement-linked healthcare models, and peers with tighter liquidity may have less room to support growth through inventory.

If collection and inventory discipline improve even modestly, BGMS could convert more revenue into cash than peers with similar demand exposure and weaker liquidity buffers.

Overall Score

BGMS is supported by strong liquidity and manageable leverage versus peers, but a very long cash conversion cycle and slow receivables collection keep forward positioning only moderately favorable.